T-M2 + T-M3

T-M2 + T-M3 is a combination or set of two novel mutant peptide-based inhibitors designed to target the TIGIT (T-cell immunoreceptor with Ig and ITIM domains) immune checkpoint. These peptides were identified through computational affinity maturation starting from the anti-TIGIT antibody MG1131, utilizing sequence sampling, molecular dynamics, and free energy calculations. T-M2 and T-M3 are engineered to block the interaction between TIGIT and its ligand CD155, thereby reversing TIGIT-mediated immunosuppression. Preclinical studies have shown that these peptides exhibit stronger inhibition of TIGIT-CD155 interactions compared to wild-type peptides and induce significantly higher levels of IFN-γ and IL-2 secretion from human CD4+ and CD8+ T cells. They are intended to provide advantages over traditional monoclonal antibodies, such as superior tissue penetration and reduced immunogenicity. The therapeutic efficacy of these peptides is currently being evaluated in preclinical tumor models, both as monotherapy and in combination with other immune checkpoint inhibitors.

Other names

TIGIT-inhibitory peptidesTIGIT-blocking peptides